MA39915A - Composés de pladiénolide pyridine et leurs procédés d'utilisation - Google Patents

Composés de pladiénolide pyridine et leurs procédés d'utilisation

Info

Publication number
MA39915A
MA39915A MA039915A MA39915A MA39915A MA 39915 A MA39915 A MA 39915A MA 039915 A MA039915 A MA 039915A MA 39915 A MA39915 A MA 39915A MA 39915 A MA39915 A MA 39915A
Authority
MA
Morocco
Prior art keywords
processes
pyridine compounds
pladienolide pyridine
pladienolide
compounds
Prior art date
Application number
MA039915A
Other languages
English (en)
Other versions
MA39915B1 (fr
Inventor
Kenzo Arai
Silvia Buonamici
Betty Chan
Nicholas C Gearhart
Baudouin Gerard
Sonobe Regina Kanada
Gregg F Keaney
Kazunobu Kira
Yoshihiko Kotake
Kian Huat Lim
Xiang Liu
Masayuki Miyano
Norio Murai
Satoshi Nagao
Eunice Sun Park
Ermira Pazolli
Sudeep Prajapati
Peter G Smith
Michael P Thomas
Parcharee Tivitmahaisoon
John Wang
Lihua Yu
Guo Zhu Zheng
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA39915A publication Critical patent/MA39915A/fr
Publication of MA39915B1 publication Critical patent/MA39915B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA39915A 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation MA39915B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
EP15727125.5A EP3143016B1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation
PCT/US2015/030464 WO2015175594A1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA39915A true MA39915A (fr) 2017-03-22
MA39915B1 MA39915B1 (fr) 2019-05-31

Family

ID=53284528

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39915A MA39915B1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Country Status (35)

Country Link
US (1) US9481669B2 (fr)
EP (2) EP3143016B1 (fr)
JP (1) JP6067943B1 (fr)
KR (2) KR101710318B1 (fr)
CN (1) CN107074827B (fr)
AR (1) AR100431A1 (fr)
AU (1) AU2015259237B2 (fr)
BR (1) BR112016026638B1 (fr)
CA (1) CA2947754C (fr)
CL (1) CL2016002835A1 (fr)
CY (1) CY1121550T1 (fr)
DK (1) DK3143016T3 (fr)
ES (1) ES2712401T3 (fr)
HR (1) HRP20190432T1 (fr)
HU (1) HUE041838T2 (fr)
IL (1) IL248529B (fr)
JO (1) JO3668B1 (fr)
LT (1) LT3143016T (fr)
MA (1) MA39915B1 (fr)
ME (1) ME03417B (fr)
MX (2) MX2020004476A (fr)
MY (1) MY195081A (fr)
PE (1) PE20170384A1 (fr)
PH (1) PH12016502249A1 (fr)
PL (1) PL3143016T3 (fr)
PT (1) PT3143016T (fr)
RS (1) RS58400B1 (fr)
RU (1) RU2707730C2 (fr)
SG (1) SG11201609693XA (fr)
SI (1) SI3143016T1 (fr)
TR (1) TR201902328T4 (fr)
TW (1) TWI634115B (fr)
UA (1) UA119458C2 (fr)
WO (1) WO2015175594A1 (fr)
ZA (1) ZA201607354B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10889866B2 (en) 2015-09-01 2021-01-12 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic SF3B1 mutants
RU2021102393A (ru) 2015-11-18 2021-03-17 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Твердые формы пладиенолидпиридиновых соединений и способы их применения
WO2018170129A1 (fr) * 2017-03-15 2018-09-20 Eisai Co., Ltd Mutations de complexes d'épissage et leurs utilisations
KR20200083532A (ko) * 2017-10-31 2020-07-08 에자이 알앤드디 매니지먼트 가부시키가이샤 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법
BR112020020792A2 (pt) 2018-04-09 2021-01-12 Eisai R&D Management Co., Ltd. Certos compostos de pladienolida e métodos de uso
SG11202009907XA (en) * 2018-04-12 2020-11-27 Eisai R&D Man Co Ltd Pladienolide derivatives as spliceosome targeting agents for treating cancer
EP3801523A2 (fr) * 2018-06-01 2021-04-14 Eisai R&D Management Co., Ltd. Procédés d'utilisation de modulateurs d'épissage
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
TW202233187A (zh) 2020-11-04 2022-09-01 日商衛材R&D企管股份有限公司 骨髓發育不良症候群(mds)之生物標記物及其使用方法
WO2022263702A1 (fr) * 2021-06-18 2022-12-22 Universidad de Córdoba Composé pour le traitement du glioblastome
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (fr) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarqueurs pour le syndrome myélodysplasique (mds) et leurs méthodes d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI311558B (en) 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
AU2003252299A1 (en) 2002-07-31 2004-02-16 Eisai Co., Ltd. Novel physiologically active substance
CN1671856B (zh) 2002-07-31 2010-05-12 卫材R&D管理株式会社 生理活性物质
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
NZ540103A (en) 2002-11-29 2007-05-31 Mercian Corp Process for producing macrolide compound
CA2546614A1 (fr) 2003-11-27 2005-06-09 Mercian Corporation Adn intervenant dans l'hydroxylation d'un compose macrolide
EP2204448B1 (fr) 2003-11-28 2012-02-22 Kanagawa Academy Of Science And Technology Procédé de détection du cancer du foie, diagnostic de cancer du foie et remède contre le cancer
EP1764592A4 (fr) 2004-07-02 2009-08-19 Plus One Techno & Co Ltd Appareil de pesage combiné
AU2005265443B2 (en) 2004-07-20 2008-09-04 Eisai R & D Management Co., Ltd DNA coding for polypeptide participating in biosynthesis of pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
JPWO2008111464A1 (ja) * 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング異常を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
MA39915B1 (fr) 2019-05-31
EP3143016B1 (fr) 2018-12-12
PT3143016T (pt) 2019-02-27
KR102146726B1 (ko) 2020-08-21
ME03417B (fr) 2020-01-20
JO3668B1 (ar) 2020-08-27
US9481669B2 (en) 2016-11-01
KR101710318B1 (ko) 2017-02-24
JP2017505282A (ja) 2017-02-16
WO2015175594A1 (fr) 2015-11-19
ZA201607354B (en) 2018-05-30
TW201625596A (zh) 2016-07-16
LT3143016T (lt) 2019-06-10
CL2016002835A1 (es) 2017-04-17
IL248529A0 (en) 2016-12-29
ES2712401T3 (es) 2019-05-13
RU2707730C2 (ru) 2019-11-29
PE20170384A1 (es) 2017-05-11
IL248529B (en) 2019-11-28
SG11201609693XA (en) 2016-12-29
RU2016148887A (ru) 2018-06-18
TWI634115B (zh) 2018-09-01
DK3143016T3 (en) 2019-04-08
AU2015259237B2 (en) 2019-08-15
MX2016014997A (es) 2017-06-29
KR20170021899A (ko) 2017-02-28
HRP20190432T1 (hr) 2019-04-19
RS58400B1 (sr) 2019-04-30
HUE041838T2 (hu) 2019-05-28
CY1121550T1 (el) 2020-05-29
EP3143016A1 (fr) 2017-03-22
EP3514154A1 (fr) 2019-07-24
BR112016026638B1 (pt) 2022-08-02
RU2016148887A3 (fr) 2018-12-11
PL3143016T3 (pl) 2019-04-30
EP3514154B1 (fr) 2022-08-03
SI3143016T1 (sl) 2019-04-30
CA2947754A1 (fr) 2015-11-19
RU2019124012A (ru) 2019-08-12
NZ764190A (en) 2023-11-24
AR100431A1 (es) 2016-10-05
AU2015259237A1 (en) 2016-11-10
NZ725603A (en) 2023-11-24
MX2020004476A (es) 2021-12-08
CA2947754C (fr) 2024-01-02
CN107074827A (zh) 2017-08-18
TR201902328T4 (tr) 2019-03-21
PH12016502249A1 (en) 2017-02-06
MY195081A (en) 2023-01-09
BR112016026638A2 (fr) 2017-08-15
KR20160082256A (ko) 2016-07-08
US20150329528A1 (en) 2015-11-19
CN107074827B (zh) 2020-12-18
UA119458C2 (uk) 2019-06-25
JP6067943B1 (ja) 2017-01-25

Similar Documents

Publication Publication Date Title
MA43827A (fr) Composés di-nucléotides cycliques et leurs procédés d'utilisation
MA39915A (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA49861A (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
MA49858A (fr) Composés, compositions et procédés
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA50063A (fr) Composés, compositions et procédés
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
MA47440A (fr) Sulfonylurées, composés apparentés, et leur utilisation
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
DK3341303T3 (da) Blisterpakning
DE112016000758A5 (de) Kupplungseinrichtung
DK3286260T3 (da) Polyolefinrør
MA41495A (fr) Composés benzoxaborole et leurs utilisations
DK3307436T3 (da) Mikrofluidanordning
DK3262182T3 (da) Modificeret creatinase
DK3274092T3 (da) Mikrofluidikanordning
FR3026108B1 (fr) Composition pour adhesif thermoplastique, adhesif thermoplastique, leurs procedes de fabrication et leurs utilisations
GB201714782D0 (en) Noy yet available
FI20165393A (fi) Ammuspakkaus
ITUB20153121A1 (it) Apparato per l'ozonoterapia
MA43036A (fr) Composés thérapeutiques et leurs procédés d'utilisation
ES1205964Y (es) Cinta de correr modular